XENE

56.84

0.02% -0.010

Handel nachbörslich: 56.84

Xenon Pharmaceuticals Inc (XENE)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$56.85

Offen:

$57.14

24-Stunden-Volumen:

1.65M

Relative Volume:

1.19

Marktkapitalisierung:

$5.42B

Einnahmen:

$7.50M

Nettoeinkommen (Verlust:

$-345.91M

KGV:

-13.04

EPS:

-4.3602

Netto-Cashflow:

$-280.51M

1W Leistung:

+2.32%

1M Leistung:

+35.53%

6M Leistung:

+43.72%

1J Leistung:

+93.33%

1-Tages-Spanne:

$56.41

$57.85

1-Wochen-Bereich:

$55.86

$59.44

52-Wochen-Spanne:

$26.74

$63.95

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Firmenname

Xenon Pharmaceuticals Inc

Sektor

Healthcare (1116)

Branche

Biotechnology (624)

Telefon

(604) 484-3300

Adresse

200 - 3650 GILMORE WAY, BURNABY

Mitarbeiter

370

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

XENE's Discussions on Twitter

Compare XENE vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
XENE Xenon Pharmaceuticals Inc	56.84	5.43B	7.50M	-345.91M	-280.51M	-4.3602
VRTX Vertex Pharmaceuticals Inc	434.30	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.04	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.25	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.34	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.81	35.01B	606.42M	-1.28B	-997.58M	-6.403

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-24	Eingeleitet	Wolfe Research	Outperform
2025-09-03	Fortgesetzt	Wells Fargo	Overweight
2025-05-07	Eingeleitet	Chardan Capital Markets	Buy
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-10-01	Eingeleitet	H.C. Wainwright	Buy
2024-01-04	Eingeleitet	Citigroup	Buy
2023-12-08	Eingeleitet	Robert W. Baird	Outperform
2023-10-24	Fortgesetzt	Cantor Fitzgerald	Overweight
2023-04-25	Eingeleitet	Cantor Fitzgerald	Overweight
2022-12-14	Eingeleitet	Goldman	Buy
2022-12-12	Eingeleitet	Cowen	Outperform
2022-11-28	Eingeleitet	Wells Fargo	Overweight
2022-10-19	Eingeleitet	Raymond James	Outperform
2022-08-29	Eingeleitet	BofA Securities	Buy
2022-07-21	Eingeleitet	JP Morgan	Overweight
2021-10-28	Eingeleitet	RBC Capital Mkts	Outperform
2020-10-02	Eingeleitet	SVB Leerink	Outperform
2020-07-21	Eingeleitet	Needham	Buy
2020-06-01	Fortgesetzt	Jefferies	Buy
2020-03-25	Eingeleitet	Wedbush	Outperform
2020-01-08	Eingeleitet	William Blair	Outperform
2019-09-20	Eingeleitet	Guggenheim	Buy
2018-08-08	Bestätigt	Stifel	Buy
2017-03-13	Eingeleitet	Jefferies	Buy
2016-10-21	Eingeleitet	Stifel	Buy
2016-09-26	Eingeleitet	Guggenheim	Buy
2016-04-14	Bestätigt	Jefferies	Buy
2015-10-30	Fortgesetzt	Jefferies	Buy
2014-12-02	Eingeleitet	Canaccord Genuity	Buy

Alle ansehen

Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten

12:40 PM

Xenon Pharmaceuticals (NASDAQ:XENE) Sees Strong Trading VolumeWhat's Next? - marketbeat.com

12:40 PM

Apr 05, 2026

Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - AOL.com

Apr 05, 2026

XENE SEC FilingsXenon Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 05, 2026

Aberdeen Group plc Increases Stock Position in Xenon Pharmaceuticals Inc. $XENE - marketbeat.com

Apr 05, 2026

Apr 04, 2026

Xenon Pharmaceuticals (XENE) climbs 31.7% as epilepsy treatment moves forward - MSN

Apr 04, 2026

XENE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

XENE PE Ratio & Valuation, Is XENE Overvalued - Intellectia AI

Apr 04, 2026

Apr 02, 2026

Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal

Apr 02, 2026

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - marketbeat.com

Apr 02, 2026

Mar 30, 2026

Xenon Pharmaceuticals stock soars 20% in 3 months: Here's why - MSN

Mar 30, 2026

How Positive Phase 3 Azetukalner Results and Upsized Financing Could Reframe Xenon Pharmaceuticals (XENE) Investors - Sahm

Mar 30, 2026

Mar 29, 2026

Assenagon Asset Management S.A. Invests $5.34 Million in Xenon Pharmaceuticals Inc. $XENE - marketbeat.com

Mar 29, 2026

Mar 28, 2026

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - marketbeat.com

Mar 28, 2026

Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 Results And US$750 Million Capital Raise - Sahm

Mar 28, 2026

Mar 27, 2026

Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - The Motley Fool

Mar 27, 2026

Xenon Pharmaceuticals (XENE) price target increased by 41.64% to 80.01 - MSN

Mar 27, 2026

Mar 25, 2026

Wolfe Research initiates coverage of Xenon Pharmaceuticals (XENE) with outperform recommendation - MSN

Mar 25, 2026

Xenon Pharmaceuticals rallies after pivotal data shows major drop in monthly seizures - MSN

Mar 21, 2026

Xenon Pharmaceuticals stock faces pipeline scrutiny amid biotech sector volatility - AD HOC NEWS

Mar 21, 2026

Mar 20, 2026

JPMorgan Chase & Co. Purchases 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE - marketbeat.com

Mar 20, 2026

Mar 19, 2026

Xenon Pharmaceuticals Shares Jump 20% Over Three Months: The Reasons Explained - Bitget

Mar 19, 2026

Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why - The Globe and Mail

Mar 19, 2026

Investors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat

Mar 19, 2026

Mar 18, 2026

Xenon Pharmaceuticals (XENE) Is Down 6.7% After $650 Million Follow-On Offering And Phase 3 Epilepsy Win - Yahoo Finance

Mar 18, 2026

Mar 17, 2026

Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 X TOLE2 Azetukalner Results - simplywall.st

Mar 17, 2026

XENE stock up as Azetukalner meets goal in focal onset seizures study - MSN

Mar 17, 2026

XENE Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 17, 2026

Jain Global LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat

Mar 17, 2026